Autoplaque vs ZEUS System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Autoplaque
by APQ Health (formerly Cedars-Sinai Medical Center: AIM)
VS
ZEUS System
by iRhythm Technologies

AI Verdict

Autoplaque is designed for analyzing CT angiography images to assess coronary plaque and stenosis for heart attack risk. In contrast, the ZEUS System focuses on continuous ECG monitoring from wearables to detect and characterize cardiac arrhythmias like Atrial Fibrillation. While both are cardiology AI tools, they address distinct cardiac conditions and utilize different data modalities for diagnosis and monitoring.

Choose Autoplaque if…

Choose Autoplaque if you require detailed, AI-powered quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. This tool is ideal for precisely assessing atherosclerotic burden, predicting heart attack risk, and guiding treatment strategies based on anatomical pathology.

View Autoplaque →

Choose ZEUS System if…

Choose the ZEUS System if your primary need is long-term, continuous cardiac rhythm monitoring to detect and characterize arrhythmias, such as Atrial Fibrillation. This cloud-based AI solution, integrated with wearable biosensors, is best suited for identifying intermittent or asymptomatic cardiac events over an extended period, facilitating early arrhythmia detection and management.

View ZEUS System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Autoplaque ZEUS System
Pricing Unknown Not disclosed
Deployment Workstation-based post-processing application, runs on Windows or Mac OS. Cloud-based (AWS EC2 platform), no on-premise hardware.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ZEUS System

The ZEUS System is cloud-based with a web portal (ZioSuite) for managing workflows and accessing reports, which generally offers greater accessibility and easier deployment than workstation-based software. Its integration with wearable devices and explicit mention of 'Ease of Use for the Physician' further suggest a streamlined user experience for continuous monitoring.

Clinical Value

Tie

Both tools are FDA-cleared and provide significant clinical value in distinct areas of cardiology. Autoplaque offers quantitative analysis of coronary plaques for heart attack risk prediction, supported by studies showing correlation with myocardial infarction. The ZEUS System provides AI-powered continuous ECG monitoring for arrhythmia detection, with high sensitivity and specificity for AFib. Both address critical needs with robust evidence.

Pricing & Value

Tie

Neither Autoplaque nor the ZEUS System has disclosed pricing information in the provided structured facts or publicly available web searches. Without any pricing details, it is impossible to conduct a meaningful comparison of their cost or assess their overall value proposition.

Enterprise Readiness

ZEUS System

The ZEUS System explicitly states HIPAA compliance, offers a Business Associate Agreement (BAA), and provides HL7-based EHR integration, which are crucial for enterprise adoption in healthcare. Its cloud-based deployment also offers scalability and reduced IT overhead compared to Autoplaque's workstation-based approach, which lacks explicit compliance and integration details.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. Autoplaque leverages deep learning for precise quantitative analysis of coronary plaques from CT angiography, aiding in advanced risk stratification. The ZEUS System innovates by integrating AI with long-term wearable ECG monitoring and cloud-based analytics for early arrhythmia detection and remote patient management.

Support & Docs

Tie

While both products mention the existence of user manuals or instructions for use (Autoplaque in FDA documents, ZEUS System in its Instructions for Use), neither provides sufficient detail in the structured facts or readily available web search results regarding the breadth of their customer support channels, documentation quality, or availability of dedicated support teams.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Autoplaque ZEUS System
Company Cedars-Sinai Medical Center: AIM iRhythm Technologies
Primary Focus Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images Analysis of ECG data from wearable biosensors for long-term continuous cardiac monitoring and arrhythmia detection
Data Source CT angiography images ECG data from wearable biosensors
Key Analysis Capabilities AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Automated vessel, plaque, and lumen segmentation AI-powered arrhythmia detection; Continuous ECG monitoring (up to 14 days); Cloud-based data analytics; Detection and characterization of Atrial Fibrillation (AFib); Preliminary report generation for physicians
Categories Cardiology AI, Radiology & Imaging AI Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties Cardiology, Radiology Cardiology, Family Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and ZEUS System.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Autoplaque is an AI-powered software designed for the quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. The ZEUS System is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, assisting in the detection and characterization of arrhythmias like Atrial Fibrillation.
Autoplaque analyzes CT angiography images to provide insights into coronary anatomy and pathology. The ZEUS System analyzes ECG data collected from wearable biosensors, such as the Zio Watch and Zio monitors.
The provided information for Autoplaque does not specify HIPAA compliance, BAA availability, or EHR integration. The ZEUS System, however, is specified as HIPAA compliant and has a Business Associate Agreement (BAA), also offering HL7-based EHR integration.
Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque, automated vessel, plaque, and lumen segmentation that is reviewable and editable by clinicians, and allows review in Multiplanar Reformatting (MPR) views. The ZEUS System offers AI-powered arrhythmia detection, continuous ECG monitoring for up to 14 days, and generates preliminary reports for physicians, supporting both symptomatic and asymptomatic cardiac events.
Autoplaque is primarily designed for use within Cardiology and Radiology specialties. The ZEUS System supports a broader range, including Cardiology, Family Medicine, and Internal Medicine.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Autoplaque or ZEUS System

Backers

Who funded each tool's parent company.

ZEUS System

AI Tool Finder
AI-powered search. Results may not be comprehensive.